HIV-1 has evolved mechanisms to evade host cell immune responses and persist for lifelong
infection. Latent cellular reservoirs are responsible for this persistence of HIV-1 despite the …

With an increasing human population, medical research is pushed to progress into an era of
precision therapy. Humanized mice are at the very heart of this new forefront where it is …

Elimination of HIV-1 requires clearance and removal of integrated proviral DNA from
infected cells and tissues. Here, sequential long-acting slow-effective release antiviral …

Treatment of HIV-1ADA-infected CD34+ NSG-humanized mice with long-acting ester
prodrugs of cabotegravir, lamivudine, and abacavir in combination with native rilpivirine was …

While HIV kills most of the cells it infects, a small number of infected cells survive and
become latent viral reservoirs, posing a significant barrier to HIV eradication. However, the …

Potent antiretroviral activities and a barrier to viral resistance characterize the human
immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir …

Background A barrier to HIV-1 cure rests in the persistence of proviral DNA in infected CD4+
leukocytes. The high HIV-1 mutation rate leads to viral diversity, immune evasion, and …

Background Despite improved clinical outcomes seen following antiretroviral therapy (ART),
resting CD4+ T cells continue to harbor latent human immunodeficiency virus type one (HIV …

Long-acting parenteral (LAP) antiretroviral drugs have generated considerable interest for
treatment and prevention of HIV-1 infection. One new LAP is cabotegravir (CAB), a highly …

Small CD4-mimetic compounds (CD4mc) sensitize HIV-1-infected cells to antibody-
dependent cellular cytotoxicity (ADCC) by facilitating antibody recognition of epitopes that …